JP3743349B2 - Volatile drug sustained release member and air conditioner using the same - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
  TECHNICAL FIELD The present invention relates to a volatile drug sustained-release member that releases a volatile drug by external humidity environment changes, and changes in seasons or changes in the atmospheric humidity environment in the field cause mold and fungi to propagate. It can be widely applied to fields where it is desired to prevent this. For example, the present invention can be applied to a bathroom, a changing room, a shoebox, a food stocker, a storeroom, an underground storage, a humidifying passage for building air conditioning, and a ventilation passage. In particular, it is effective to keep the indoor unit of the air conditioner always clean after the cooling operation.
[0002]
[Prior art]
  Various techniques have been proposed for gradually releasing the filled liquid over a long period of time. In general, it is a method in which a porous material is impregnated and gradually volatilized by capillary action. The porous material was an inorganic compound such as zeolite or silica gel, or a foam or fiber bundle of polypropylene, polyester or cellulose. Further, a method for gradually releasing an organic substance called cyclodextrin by inclusion in a small hole has been proposed in Japanese Patent Application Laid-Open Nos. 5-176733 and 6-40890. Also, methods for microencapsulation to realize sustained release are disclosed in JP-A-6-9377, JP-A-6-65064, JP-A-7-89848, JP-A-9-911, and JP-A-9-. No. 12447, JP-A-9-57091, and the like.
[0003]
  Further, when a sucker is used, as a method often used in the field of insect repellent or fragrance, the sucker is heated with a heater to further improve the volatilization rate. This is proposed in Japanese Patent Laid-Open No. 63-240738.
[0004]
[Problems to be solved by the invention]
  However, in the above conventional configuration, it was not possible to stably and slowly release a low concentration volatile drug according to an external humidity environment change. The amount of drug solution is large. At first, a large amount of drug is volatilized, and as time passes, the release amount tends to decrease due to the change in drug decrease. It had the problem that it was not done.
[0005]
  The present invention is a volatilizing drug sustained-release member that can average the drug vapor at a low concentration release rate and volatilize and slowly release the conventional problem, and is unnecessary because it can sufficiently cope with humidity change. Excessive release of time can be suppressed. Further, the volatile component is secondarily released from the member so as to be less affected by the release amount even when the liquid amount of the drug is reduced.
[0006]
[Means for Solving the Problems]
  In response to the above problems, a liquid absorber that absorbs and holds a liquid medicine, a volatilization amount control film that controls the volatilization amount of the medicine on the exterior of the liquid absorber, and a permeation amount of the medicine changes due to a change in humidity. A moisture-sensitive film, and a space is provided between the volatilization amount control film and the humidity-sensitive film to hold the vapor of the drug volatilized, and the drug is volatilized to be constant in the space part. A volatilizing drug sustained-release member in which the drug staying in the space portion is gradually released from the humidity-sensitive film to the outside in accordance with an external humidity environment change while being kept at a vapor concentration or less.
[0007]
  With the above configuration, the volatile drug is absorbed and held by the liquid absorber, so that the direction of the volatile drug sustained release member can be handled in any case, and the vapor volatilization amount of the drug is the primary provided on the exterior surface. Concentration is controlled by the control membrane, and the volatilized component fills and stays in a space having a certain volume. If the external humidity is low and the drug vapor filled from this space is not released to the outside, the amount finally released to the outside from the volatile drug sustained release member is controlled to almost the saturated vapor pressure concentration state or less. Can be suppressed. Further, when the external humidity is high, the chemical vapor that has been volatilized and filled is transmitted through the humidity-sensitive film serving as the secondary control film and released to the outside. Thus, the volatile chemical | medical agent sustained release member excellent in discharging | emitting a low concentration chemical | medical agent vapor | steam according to humidity from the high concentration space part of a volatile chemical | medical agent vapor | steam can be provided. Specifically, it is effective for the purpose of releasing 100 mg / day level at 30 ° C. and 95% relative humidity. In addition, since the chemical vapor is volatilized into the space where it is once filled and retained, and then released to the outside, it is a secondary sustained-release diffusion system, so even if the liquid volume of the drug gradually changes, the liquid absorber The liquid surface and the space in the primary control film are concentration controlled by gas-liquid equilibrium. Therefore, the volume of the space formed by the primary control film and the secondary control film is larger than the maximum space volume generated by the change in the amount of drug solution inside the primary control film, thereby releasing from the volatile drug sustained release member. The amount of change in drug vapor concentration over time can also be significantly reduced.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
  The invention described in claim 1Liquid that is allyl isothiocyanate, tea tree oil or eucalyptus oilAbsorbs and retains drugsLiquid with volume swell of 200% or moreAn absorbent body, a volatilization amount control film that controls the volatilization amount of the drug on the exterior of the liquid absorber, and a humidity sensitive film that changes the permeation amount of the drug due to humidity change,The liquid absorber is a continuous porous body of polyurethane, polypropylene, polyethylene or polyvinyl alcohol,A space is provided between the volatilization amount control film and the humidity sensitive film to store the vapor of the chemical vaporized, and the chemical vaporizes.The volatilization amount control film and the humidity sensitive film formed with theA volatilizing drug slow release member in which the drug staying in the space part is gradually released from the humidity sensitive film to the outside in response to a change in the external humidity environment while being kept below a certain vapor concentration in the space part. is there.
[0009]
  The invention according to claim 2 is an indoor unit having at least a heat exchanger and an indoor fan for blowing out the air temperature-controlled by the heat exchanger into the room.Liquid that is allyl isothiocyanate, tea tree oil or eucalyptus oilAbsorbs and retains drugsLiquid with volume swell of 200% or moreComprising an absorber, a film for controlling the volatilization amount of the drug on the exterior of the liquid absorber, and a humidity sensitive film in which the permeation amount of the drug changes due to humidity change,The liquid absorber is a continuous porous body of polyurethane, polypropylene, polyethylene or polyvinyl alcohol,Between the volatilization amount control film and the humidity sensitive film, a space is provided for the vapor of the chemical vaporized to stay, and the chemical vaporizes.The volatilization amount control film and the humidity sensitive film formed with theThe drug staying in the space is gradually released from the humidity-sensitive membrane to the outside in response to changes in the external humidity environment while being kept below a certain vapor concentration in the space.Be doneVolatile drug sustained release member,Near the heat exchangerIt is an air conditioner arranged on the upstream side.
[0010]
  The invention according to claim 3 provides the liquid.The average pore diameter of the continuous porous body that becomes the absorber is 10 to 100 μm, and the porosity is 50 to 90%.Volatile drugIt is a sustained release member.
[0011]
  The invention according to claim 4The film for controlling the volatilization amount of the drug is a polyethylene film, a polypropylene film, a polyurethane film, a nylon film, a polyethylene terephthalate film or a composite laminate film thereof.A volatile drugIt is a sustained release member.
[0012]
  The invention according to claim 5The humidity sensitive film has a laminate structure including viscose processed paper on the surface.A volatile drugIt is a sustained release member.
[0013]
  The invention described in claim 6The release amount of the drug is 30 to 200 ° C. and a relative humidity of 95% at 20 to 200 mg / day.A volatile drugIt is a sustained release member.
[0014]
  The invention described in claim 7The release amount of the drug is 10 mg / day or less at 30 ° C. and 30% relative humidity.A volatile drugIt is a sustained release member.
[0015]
  The invention described in claim 8A container that can visualize the reduced state where the liquid medicine changes in weight.A volatile drugIt is a sustained release member.
[0016]
  The invention according to claim 9A non-permeable film is deposited on the surface of the humidity sensitive membrane. As an outer bag, in use, the moisture sensitive membrane is exposed by peeling off the non-permeable film.A volatile drugIt is a sustained release member.
[0017]
  The invention according to claim 10 is:Air in which the ratio of the space for retaining the chemical vapor inside the volatile chemical sustained release member and the space volume inside the indoor unit is 1: 500 to 5000 timesIt is a harmony machine.
[0018]
  The invention according to claim 11The humidity sensitive membrane surface of the volatile drug sustained release member was placed so as to face the upstream side surface of the heat exchanger.It is an air conditioner.
[0019]
【Example】
  Embodiments of the present invention will be described below with reference to the drawings.
[0020]
  (Example 1)
  FIG. 1 is a front external view of a volatile drug sustained release member according to the present embodiment, and FIG. 2 is a side sectional configuration diagram of the volatile drug sustained release member. Reference numeral 1 denotes a polyurethane continuous porous body that has swelled by absorbing allyl isothiocyanate serving as a drug. Specifically, 35 × 71 × 2 polyurethane continuous porous material, bulk density 0.35g / ml, average pore diameter 30μm, porosity 70%, absorb 15.5g allyl isothiocyanate and swell to about 50 × 100 × 2.8 did. 2 is a container made of colorless and transparent polyethylene terephthalate (PET) for filling it, and an amorphous PET sheet having a thickness of 1 mm was processed by vacuum forming. Reference numeral 3 denotes a laminate film for controlling the volatilization amount of allyl isothiocyanate from the polyurethane continuous porous material, and the structure is composed of 30 μm polypropylene and 70 μm polyethylene, and becomes a primary control film. The outer peripheral portion of the laminate film 3 is welded and joined to the PET container 2 by heat sealing the polyethylene side. Reference numeral 4 denotes a humidity sensitive film obtained by laminating viscose processed paper on polyethylene, which is a secondary control film. The outer periphery of the humidity sensitive film 4 is also welded and joined to the PET container 2 by heat sealing the polyethylene side. Humidity sensitive film 4 is polyethylene film 30μm, viscose film 7g / m via rayon / pulp nonwoven fabric²What was formed with the application quantity of was used. Reference numeral 5 denotes a space formed by the laminate film 3 and the humidity sensitive film 4, and the space volume is 30 ml. The allyl isothiocyanate vapor volatilized from the polyurethane continuous porous material reaches the space formed by the laminate film 3 and the humidity sensitive film 4 while the volatilization amount is suppressed by the laminate film 3. For example, since the vapor pressure of allyl isothiocyanate is about 5 mmHg at 25 ° C., the inside of the primary control membrane immediately has a maximum saturated vapor concentration of about 6600 ppm, and the space portion 5 has a certain concentration gradient with respect to it. If the isothiocyanate vapor is filled and the release amount from the secondary control membrane is small, the volatilization amount increases to the vapor pressure characteristic with respect to the atmospheric temperature to some extent, and finally, the space part 5 can reach almost the saturated vapor pressure concentration. . In the case of low humidity, the humidity sensitive film 4 suppresses vapor release of allyl isothiocyanate to the outside to some extent, so that the space portion 5 is maintained in a state close to the saturated vapor pressure concentration. However, when the humidity increases, the allyl isothiocyanate vapor easily passes through the humidity sensitive membrane 4 and is released to the outside. The humidity sensitive membrane 4 has a loose structure due to swelling of the membrane structure due to a change in humidity, and allyl isothiocyanate molecules are easily permeated and released to the outside. In order to replenish this released amount, it is necessary that the allyl isothiocyanate vapor volatilized from the polyurethane continuous porous material further passes through the laminate film 3 and fills the space 5. At this time, when the allyl isothiocyanate release rate from the humidity sensitive membrane 4 to the outside and the allyl isothiocyanate volatilization rate permeating the allyl isothiocyanate volatilized from the polyurethane continuous porous material into the space part 5 are compared, the latter is faster. There is no shortage of allyl isothiocyanate release. The volatile drug sustained-release member having such a configuration makes it possible to continuously release the drug from the humidity-sensitive film at a level of 100 mg / day at 30 ° C. and a relative humidity of 95%. Further, the drug release characteristics from the volatile drug sustained-release member hardly changed until the remaining amount of allyl isothiocyanate was 10 wt% or less with respect to the initial stage.
[0021]
  Next, the case where the volatile chemical | medical agent sustained release member by a present Example is used for the indoor unit of an air conditioner is demonstrated.
[0022]
  FIG. 4 is a cross-sectional configuration diagram of the indoor unit of the air conditioner showing the present embodiment. The indoor air is sucked in through the suction grills 6 and 7, and the sucked air is cooled and dehumidified by the heat exchangers 8 and 9, and then sucked and blown by the cross flow fan 10 to provide cool air from the final outlet 11 to the indoor space. To do. Upper and lower deflection blades 12 are disposed at the outlet 11 to control the direction of blowing into the indoor space. At this time, the dewed water dehumidified by the heat exchangers 8 and 9 reaches the drain pan portions 13 and 14 through the heat exchanger aluminum fins. The drain pan 13 is configured as an integral part of the indoor unit frame 15, and the drain pan 14 is configured as an integral part of the blowing grill 16. Condensed water collected in the drain pan 13 flows to the drain pan 14 via the underframe 15 and is received by water, and finally discharged to the outside via a drain port (not shown). The aluminum fins of the heat exchangers 8 and 9 have a structure in which vertical slits are provided in order to increase the efficiency of heat exchange performance. For this reason, the condensed water forms a water film by surface tension at the slit portion, and is difficult to drip immediately onto the drain pan portions 13 and 14, so that the aluminum fins dry and the speed becomes slow. For example, in an environmental atmosphere of 25 ° C. and a relative humidity of 90%, it takes several tens of hours for the heat exchanger aluminum fins to dry and does not readily dry. At this time, the indoor unit space, particularly the inside of the blower circuit constituted by the heat exchangers 8 and 9, is exposed to an atmosphere having a relative humidity of 95% or more, which is an environmental condition in which molds are very easy to propagate. Reference numeral 17 denotes a volatile drug sustained release member, which is disposed on the lower upstream side in the vicinity of the heat exchanger 9 and has a configuration in which the humidity sensitive film 4 side of the volatile drug sustained release member 17 faces the heat exchanger. Thus, after the cooling and dehumidifying operations are stopped, the upper and lower deflection blades 12 are closed, and when the air in a high humidity state fills the entire indoor unit and reaches the humidity sensitive film 4, the volatile drug sustained release member Since allyl isothiocyanate 1 diffuses from the inside of 17 to the heat exchanger 9 side and passes between the aluminum fins, the upper and lower deflection blades 12 are in a closed state, so that the space portion constituted by the heat exchangers 8 and 9 is used. It gradually spreads and accumulates to etc. As a result, the interior of the indoor unit can retain allyl isothiocyanate vapor of about 3 to 5 ppm at the bottom of the space constituted by the heat exchangers 8 and 9 and 1 ppm or more in the upper low concentration space. The high concentration allyl isothiocyanate vapor staying in the space portion 5 of the volatile drug gradual release member 17 passes through the humidity sensitive film 4 and diffuses into the space of 500 to 5000 times. Since the threshold value of allyl isothiocyanate is about 10 ppm, the residence concentration is at a level where no odor is felt. As a result, it was possible to obtain a sufficient fungicidal effect on common molds such as Cladosporium, Alternaria, Aspergillus, Penicillium and Rhizopus present in the indoor space. In order to obtain an antifungal effect, the allyl isothiocyanate vapor to the indoor unit is desirably 0.5 ppm or more, and practically desirable to be 10 ppm or less, which is a human threshold. Therefore, it is considered that the ratio of the space where the chemical vapor stays inside the volatile drug sustained release member and the space volume inside the indoor unit is preferably about 1: 500 to 5000 times.
[0023]
  Since the liquid amount of the medicine uses a transparent amorphous PET resin in the container, the user can observe the shape of the polyurethane continuous porous body by visual observation. The weight loss state can be easily confirmed at any time according to the amount of change in the size of the polyurethane continuous porous body, so that it is possible to easily determine the replacement time.
[0024]
  In the embodiment, the humidity sensitive film of the volatile drug sustained release member is disposed on one side, and the humidity sensitive film side faces the suction upstream surface of the heat exchanger, but the present invention is not limited to this. . However, considering replacement of the volatilizing drug slow release member when the drug runs out, maintenance by the user is improved by disposing the suction grill 7 on the upstream side of the heat exchanger. In order to efficiently use the drug and to release it quickly, it is most desirable to adopt the configuration as in this embodiment.
[0025]
  (Example 2)
  FIG. 4 is a front external view of the volatile drug sustained-release member according to the present embodiment, and FIG. 5 is a side cross-sectional configuration diagram of the volatile drug sustained-release member. Reference numeral 18 denotes a polyurethane continuous porous material that has swelled by absorbing allyl isothiocyanate. Specifically, 35 × 71 × 2 polyurethane continuous porous material, bulk density 0.35g / ml, average pore diameter 30μm, porosity 70%, absorb 15.5g allyl isothiocyanate and swell to about 50 × 100 × 2.8 did. 19 is a pillow package of a laminate film that becomes the exterior of the polyurethane continuous porous body 18. The laminate side of polypropylene 30 μm and polyethylene 70 μm is made by pillow-wrapping the polyethylene side by heat sealing, and is the primary control. Become a film. 20 is a container made of colorless and transparent amorphous PET for filling it, and was processed by injection molding. Reference numeral 21 denotes a PP locking pin for fixing and holding the laminated film pillow package 19 to the PET container 20, and has a structure to be fitted into the PET container. Reference numeral 22 denotes a humidity sensitive film obtained by laminating viscose processed paper on polyethylene, which is a secondary control film and has the same configuration as that of the first embodiment. Reference numeral 23 denotes a space for filling and retaining allyl isothiocyanate volatilized from the pillow package, and its space volume is 30 ml. The allyl isothiocyanate volatilized from the polyurethane continuous porous body 18 reaches the space formed by the laminate film 19 and the humidity sensitive film 22 while the volatilization amount is suppressed by the laminate film 19. Therefore, it is volatilized with a vapor pressure characteristic with respect to the atmospheric temperature to some extent, and finally the space 23 is made to reach a substantially saturated vapor pressure concentration. In the case of low humidity, the humidity sensitive film 22 suppresses the release of allyl isothiocyanate to the outside to some extent, so that the space portion 23 is maintained in a state close to the saturated vapor pressure concentration. However, when the humidity increases, allyl isothiocyanate vapor easily passes through the humidity sensitive membrane 22 and is released to the outside. The humidity-sensitive membrane 22 swells and becomes loose due to changes in humidity, and allyl isothiocyanate molecules are easily permeated and released to the outside. In order to replenish this released amount, it is necessary that allyl isothiocyanate volatilized from the polyurethane continuous porous body 18 further passes through the pillow package 19 of the laminate film and fills the space 23. At this time, comparing the release rate of allyl isothiocyanate from the humidity-sensitive membrane 22 to the outside and the allyl isothiocyanate volatilization rate at which the allyl isothiocyanate volatilized from the polyurethane continuous porous material 18 permeates into the space 23 is higher, the latter is faster. The amount of allyl isothiocyanate released is not insufficient. The volatile drug sustained-release member having such a configuration makes it possible to continuously release the drug from the humidity-sensitive film at a level of 100 mg / day at 30 ° C. and a relative humidity of 95%.
[0026]
  In this embodiment, PP fixing pins are used to fix the pillow film package of the laminate film to the PET container, but it is also possible to fix the bottom of the PET container and the pillow package with double-sided tape or hot melt.
[0027]
  (Example 3)
  FIG. 6 is a front external view of the volatile drug sustained release member shown in FIG. 6, and FIG. 7 is a side cross-sectional configuration diagram of the volatile drug sustained release member. Reference numeral 24 denotes a polyurethane continuous porous material that has swelled by absorbing allyl isothiocyanate. Specifically, 35 × 71 × 2 polyurethane continuous porous material, bulk density 0.35g / ml, average pore diameter 30μm, porosity 70%, absorb 15.5g allyl isothiocyanate and swell to about 50 × 100 × 2.8 did. 25 is a four-way deep-drawn packaged body of laminated film that becomes the exterior of the polyurethane continuous porous body 24. The laminated film of polypropylene 30 μm and polyethylene 70 μm is four-sided deep-drawn by heat sealing on the polyethylene side. It becomes the primary control film. 26 is a container made of colorless and transparent amorphous PET for filling it, and a PET film having a thickness of 1 mm was processed by vacuum forming. Reference numeral 27 denotes a humidity sensitive film obtained by laminating viscose processed paper on polyethylene, which is a secondary control film, and has the same configuration as in the first embodiment. 28 is a space for filling and staying allyl isothiocyanate volatilized from the four-way deep-drawn package, and its space volume is 30 ml. The outer peripheral portion of the humidity sensitive film 27 is welded and joined to the PET container 26 by heat sealing together with the outer peripheral portion of the four-way deep-drawn package 25 as a sandwich structure. 29 is a double-sided tape, which joins the bottom surface of the four-way deep-drawn package and the bottom surface of the PET container 26 for safety.
[0028]
  In this example, double-sided tape was used to fix the laminated film four-way deep-drawn package to the PET container, but the bottom part of the PET container and the bottom part of the four-way deep-drawn package can also be fixed with hot melt. It is.
[0029]
  (Example 4)
  FIG. 8 is a front external view of the volatile drug sustained release member shown in FIG. 8, and FIG. 9 is a side cross-sectional configuration diagram of the volatile drug sustained release member. Since the main body configuration of the volatile drug sustained-release member is substantially the same as that of Example 1, detailed description is omitted and only the difference will be described. Reference numeral 30 denotes a non-permeable film made of polyethylene / nylon / aluminum foil / polyethylene structure, which is hot-plate welded to the PET container 2 so as to cover the humidity sensitive film 4 to prevent leakage of allyl isothiocyanate vapor. A part of the non-permeable film 30 has an intentional protruding portion from the PET container 2, and has a structure in which the non-permeable film 30 can be easily peeled by sandwiching the protruding portion. At the time of use, the following functions can be achieved by peeling the non-permeable film 30 from the volatile drug sustained release member. The allyl isothiocyanate volatilized from the polyurethane continuous porous material reaches the space formed by the laminate film and the humidity sensitive film while the volatilization amount is suppressed by the laminate film. Therefore, it volatilizes to some extent with the vapor pressure characteristics with respect to the ambient temperature, and finally the space is made to reach almost the saturated vapor pressure concentration. The moisture-sensitive membrane suppresses the release of allyl isothiocyanate to a certain extent in the case of low humidity, so that the space is maintained while being close to the saturated vapor pressure concentration. However, when the humidity increases, allyl isothiocyanate vapor passes through the humidity sensitive membrane and is released to the outside. In order to replenish this released amount, allyl isothiocyanate is further volatilized from the polyurethane continuous porous material, and is filled into the space through the laminate film.
[0030]
  In the examples, a colorless and transparent amorphous PET resin was used as a container for filling the drug, but the present invention is not limited to this. In addition, a material having no problem may be selected in view of chemical resistance with the medicine to be filled. In addition, a polypropylene resin, a polycarbonate resin, a polyethylene naphthalate resin, a polyethylene resin, a methylpentene resin, and the like can be used as transparent resins so that the amount of the drug can be easily visually confirmed. However, amorphous PET resin can be obtained at low cost because it can be easily used as a container for a volatile drug sustained-release member by molding a sheet-like material by vacuum processing or press processing.
[0031]
  In the examples, a continuous porous body of polyurethane was used as the liquid absorber, but the present invention is not limited to this. There is no particular problem as long as it is a material that adsorbs and holds a liquid drug and sufficiently expands the volume. Moreover, even if a volatile chemical | medical agent is adsorbed and hold | maintained for a long period, the original shape as a continuous porous body can be maintained, and what shrinks gradually as the chemical | medical agent currently hold | maintains is reduced. In addition, since the present invention intends to gradually release a substance composed of plant essential oil or the like at a low concentration, it is preferable that a substance having excellent lipophilicity can increase the liquid retention rate. Specifically, if a continuous porous body has an average pore size of 10 to 100 μm and a porosity of 50 to 90% as physical properties, the liquid retention of the drug is 100% or more by volume ratio, and the volume swelling ratio is 200%. The above effects can be obtained. As a tendency, the volume expansion coefficient could be increased by having many small pore diameters. In addition, the volume expansion coefficient can naturally be increased as the porosity increases, but if the porosity is increased too much, the mechanical strength becomes too weak and the shape collapses. In addition to polyurethane, polypropylene, polyethylene, polyvinyl alcohol, and the like can be used as the continuous porous body, but the ease of elongation when holding a liquid varies depending on the type of resin. The polyurethane continuous porous body was the easiest to stretch. These liquid absorbers undergo sufficient volume expansion in the initial stage, and gradually shrink as the retained drug is reduced. As a result, the user visually observes the volatile drug sustained-release member from the outside, thereby remaining the drug residue. Since the amount of liquid can be grasped, the replacement time to be replaced can be recognized. Moreover, even if it is used practically for a long time, the original shape as a continuous porous body can be maintained.
[0032]
  In the examples, a composite laminate film of polypropylene and polyethylene was used as a film for controlling the volatilization amount of the drug, but what can be used in the present invention is not limited to this. In addition, a polyethylene film, a polypropylene film, a polyurethane film, a nylon film, or a polyethylene terephthalate film can be used alone or in combination as a film having a laminate structure.
[0033]
  In the examples, allyl isothiocyanate was exclusively used, but the present invention is not limited to this. Tea tree oil, eucalyptus oil, etc. can be used. Moreover, if it is a chemical | medical agent which can obtain an antibacterial and antifungal effect by a low concentration volatilization amount, it can be utilized as a chemical | medical agent of the volatile chemical | medical agent sustained release member of this invention.
[0034]
  In the examples, a film made of polyethylene / nylon / aluminum foil / polyethylene structure was used as the non-permeable film, but the film that can be used in the present invention is not limited to this. However, in general, a laminated film having an inner layer of an aluminum foil of 5 μm or more is used as the non-permeable film. In the present invention, the non-permeable film can be easily removed from the container of the volatile drug sustained-release member by using a material excellent in hot plate weldability or ultrasonic weldability with the resin that becomes the container of the volatile drug sustained-release member. Only peelable.
[0035]
  In the examples, only the case where the present invention is applied to an indoor unit of a general separate type air conditioner has been described, but the application of the volatile drug sustained release member according to the present invention is not limited to this. It can be widely used in fields where it is desired to prevent the growth of mold and fungi due to seasonal fluctuations or changes in the ambient humidity environment. For example, it can be used in bathrooms, changing rooms, clogs boxes, food stockers, storerooms, underground storage. It can also be applied to humidification passages and ventilation passages for building air conditioning.
[0036]
【The invention's effect】
  As is clear from the above example,The present inventionAccording to the present invention, the volatile drug is absorbed and held by the liquid absorber, so that the volatile drug sustained release member can be used in any direction, and the vapor volatilization amount of the drug is the primary provided on the exterior surface. Concentration is controlled by the control membrane, and the volatilized component fills and stays in a space having a certain volume. If the external humidity is low and the drug vapor filled from this space is not released to the outside, the amount finally released to the outside from the volatile drug sustained release member is controlled to almost the saturated vapor pressure concentration state or less. Can be suppressed. Further, when the external humidity is high, the chemical vapor that has been volatilized and filled is transmitted through the humidity-sensitive film serving as the secondary control film and released to the outside. Thus, the volatile chemical | medical agent sustained release member excellent in discharging | emitting a low concentration chemical | medical agent vapor | steam according to humidity from the high concentration space part of a volatile chemical | medical agent vapor | steam can be provided. Specifically, it is effective for the purpose of releasing 100 mg / day level at 30 ° C. and 95% relative humidity. In addition, the chemical vapor is volatilized once into the space where it is filled and retained, and then released to the outside, so it is a secondary sustained release diffusion system, so even if the liquid volume of the drug gradually changes, the liquid absorber The liquid surface and the space in the primary control film are controlled by gas-liquid equilibrium. Therefore, the volume of the space formed by the primary control film and the secondary control film is larger than the maximum space volume generated by the change in the amount of drug solution inside the primary control film, thereby releasing from the volatile drug sustained release member. The amount of change in the drug vapor concentration over time was also significantly reduced.
[0037]
  In addition, the present inventionTherefore, it is possible to suppress wasteful release of the drug in the low humidity season, and to keep the drug stably and slowly released at a low concentration in a high humidity season or atmospheric conditions. It was possible to prevent the fungus from breeding for a long time.
[0038]
  In addition, the present inventionAccording to the above, by using a continuous porous body having a high foaming degree, the drug is sufficiently absorbed and retained, and swells to a large volume expanded shape. As a result, when the drug was volatilized and reduced in volume, the change in the liquid amount could be easily confirmed by visual observation.
[0039]
  In addition, the present inventionAccording to the above, by setting the average pore diameter to 10 to 100 μm and the porosity to 50 to 90% as the physical properties of the continuous porous body, the liquid retention of the drug becomes 100% or more by volume ratio, and a sufficient volume swelling effect is obtained. I was able to get it.
[0040]
  In addition, the present inventionAccording to the present invention, the liquid absorbent is a continuous porous body of polyurethane, polypropylene, polyethylene or polyvinyl alcohol, so that the continuous porous body can guarantee a sufficient liquid holding capacity, and the arrangement or orientation of the members changes. However, there is no practical problem. In addition, the original shape of the continuous porous body can be maintained even if it is used for a long time in practical use, and the user can easily visually check the remaining amount of the drug because it gradually contracts as the remaining amount of the drug changes. It was.
[0041]
  In addition, the present inventionAccording to the above, a sufficient sustained release effect can be obtained by using a polyethylene film, a polypropylene film, a polyurethane film, a nylon film, a polyethylene terephthalate film or a composite laminate film thereof as a primary control film for controlling the volatilization amount of a liquid drug. I was able to.
[0042]
  In addition, the present inventionAccording to the above, by using allyl isothiocyanate, tea tree oil, and eucalyptus oil as a drug, it was possible to provide an environmentally friendly antibacterial and antifungal effect by using a natural component at a low concentration.
[0043]
  In addition, the present inventionAccording to the present invention, it was possible to provide a humidity sensitive film sensitive to humidity by using a humidity sensitive film having a laminate structure containing viscose processed paper.
[0044]
  In addition, the present inventionAccording to the above, if the amount of drug released is 30 ° C. and 20% to 200 mg / day at 95% relative humidity, it will be sustainedly released at a level equal to or lower than the human threshold, depending on the type of drug. By doing so, the target effect of the drug can be obtained, so that the user can also have a good impression.
[0045]
  In addition, the present inventionAccording to the above, if the release amount of the drug is 10 mg / day or less at 30 ° C. and a relative humidity of 30%, it is possible to suppress the release of useless drug under low humidity conditions, so that the replacement and replacement period is extended. be able to.
[0046]
  In addition, the present inventionAccording to the above, for example, by using a transparent container so that the amount of liquid inside can be visualized, the amount of liquid of the medicine can be easily visually confirmed, and the user can be notified of the replacement time.
[0047]
  In addition, the present inventionAccording to the present invention, the non-permeable film is welded to the upper surface of the humidity-sensitive film to form an outer bag, and in use, the non-permeable film is peeled off to expose the humidity-sensitive film. The minimum necessary simple packaging form for the release member could be provided.
[0048]
  In addition, the present inventionAccording to the above, by optimizing the volume relationship between the high-concentration space where the chemical vapor stays and the space to be released, a sufficient fungicidal effect can be obtained, and the air conditioner user is also uncomfortable. We were able to provide an environment without
[0049]
  In addition, the present inventionAccording to the above, by directing the humidity sensitive membrane surface of the volatile drug sustained release member to the heat exchanger side, it is possible to quickly feel the humidity increase from the heat exchanger side and improve the sustained release response of the drug. did it.
[Brief description of the drawings]
1 is a front external view of a volatile drug sustained-release member of Example 1. FIG.
2 is a side cross-sectional configuration diagram of a volatile drug sustained-release member of Example 1. FIG.
FIG. 3 is a cross-sectional configuration diagram of an indoor unit of the air conditioner according to the first embodiment.
4 is a front external view of a volatile drug sustained release member of Example 2. FIG.
5 is a side cross-sectional configuration diagram of a volatile drug sustained-release member of Example 2. FIG.
6 is a front external view of the volatile drug sustained-release member of Example 3. FIG.
7 is a side cross-sectional configuration diagram of the volatile drug sustained-release member of Example 3. FIG.
FIG. 8 is a front external view of a volatile drug sustained-release member of Example 4.
9 is a side cross-sectional configuration diagram of a volatile drug sustained-release member of Example 4. FIG.
[Explanation of symbols]
  1 Polyurethane continuous porous body
  3 Laminate film
  4 Humidity sensitive membrane
  5 spaces
  6 Suction grill
  7 Suction grill
  8 Heat exchanger
  9 Heat exchanger
  10 Cross flow fan
  11 Outlet
  16 Outlet grill
  17 Volatile drug sustained release member
  18 Polyurethane foam
  19 Pillow package of laminated film
  22 Humidity sensitive membrane
  23 Space
  24 Polyurethane foam
  25 Four-way deep-drawn package of laminate film
  27 Humidity sensitive membrane
  28 Space
  29 Double sided tape
  30 Non-permeable film

Claims (11)

A liquid absorbent that has been swelled by 200% or more by absorbing and holding a liquid drug that is allyl isothiocyanate, tea tree oil, or eucalyptus oil, and a volatilization amount control that controls the volatilization amount of the drug on the exterior of the liquid absorber. And a humidity sensitive film in which the permeation amount of the drug changes due to humidity change, and the liquid absorber is a continuous porous body of polyurethane, polypropylene, polyethylene or polyvinyl alcohol, and the volatilization amount control film and the above A space for the vapor of the chemical vaporized to stay between the moisture-sensitive film is provided, and the chemical is volatilized and is constant in the space formed by the volatilization amount control film and the humidity-sensitive film . While being kept at a vapor concentration or lower, the drug staying in the space is gradually released from the humidity sensitive film to the outside in accordance with external humidity environment changes. Volatile drug sustained-release member, characterized in that. In an indoor unit having at least a heat exchanger and an indoor fan for blowing the air temperature-controlled by the heat exchanger into the room , the liquid medicine which is allyl isothiocyanate, tea tree oil or eucalyptus oil is absorbed and retained. A liquid absorber having a volume swelled by 200% or more, a film for controlling the volatilization amount of the drug on the exterior of the liquid absorber, and a humidity-sensitive film in which the permeation amount of the drug changes due to a change in humidity. The liquid absorber is a continuous porous body of polyurethane, polypropylene, polyethylene, or polyvinyl alcohol, and a space for storing vapor of the drug volatilized between the volatilization amount control film and the humidity sensitive film is provided. provided, wherein the agent is kept below a certain vapor concentration in the space part formed by the by volatilization the volatilized amount control layer and the humidity sensitive film Reluctant, the volatile drug sustained-release member drug remaining in the said space in response to an external humidity environmental changes are slow release to the outside from the humidity-sensitive film was placed on the upstream side of the heat exchanger near An air conditioner characterized by that. 2. The volatile drug sustained-release member according to claim 1, wherein the continuous porous body serving as the liquid absorber has an average pore diameter of 10 to 100 μm and a porosity of 50 to 90% . The volatile drug sustained-release member according to claim 1 , wherein the film for controlling the volatilization amount of the drug is a polyethylene film, a polypropylene film, a polyurethane film, a nylon film, a polyethylene terephthalate film, or a composite laminate film thereof. . The volatile drug sustained-release member according to claim 1 , wherein the humidity-sensitive film has a laminate structure including viscose-processed paper on the surface . 2. The volatile drug sustained-release member according to claim 1 , wherein the release amount of the drug is 20 to 200 mg / day at 30 ° C. and a relative humidity of 95% . The volatile drug sustained-release member according to claim 1 , wherein the drug release amount is 10 mg / day or less at 30 ° C and a relative humidity of 30% . 2. The volatile drug sustained-release member according to claim 1 , wherein the volatile drug sustained-release member is a container capable of visualizing a reduced state in which the liquid drug is changed in weight . The non-permeable film is welded to the upper surface of the humidity-sensitive film to form an outer bag, and the humidity-sensitive film is exposed by peeling the non-permeable film in use. volatile sustained drug release member according to. The air conditioner according to claim 2, wherein a ratio of a space for storing the chemical vapor inside the volatile chemical sustained-release member and a space volume inside the indoor unit is 1: 500 to 5000 times. Machine. The air conditioner according to claim 2, wherein the humidity sensitive membrane surface of the volatile drug sustained release member is disposed so as to face the upstream side surface of the heat exchanger .

Images